Form 8-K - Current report:
SEC Accession No. 0001683168-22-001424
Filing Date
2022-03-03
Accepted
2022-03-03 17:15:17
Documents
16
Period of Report
2022-02-25
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT phio_8k.htm   iXBRL 8-K 29435
2 LETTER FROM NASDAQ LISTINGS QUALIFICATION DEPARTMENT DATED FEBRUARY 25, 2022 phio_ex9901.htm EX-99.1 20906
6 GRAPHIC image_001.jpg GRAPHIC 14272
7 GRAPHIC image_002.jpg GRAPHIC 4061
8 GRAPHIC image_003.jpg GRAPHIC 4456
  Complete submission text file 0001683168-22-001424.txt   260873

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE phio-20210812.xsd EX-101.SCH 3039
4 XBRL LABEL FILE phio-20210812_lab.xml EX-101.LAB 34476
5 XBRL PRESENTATION FILE phio-20210812_pre.xml EX-101.PRE 22599
10 EXTRACTED XBRL INSTANCE DOCUMENT phio_8k_htm.xml XML 3604
Mailing Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752
Business Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752 (508) 767-3861
Phio Pharmaceuticals Corp. (Filer) CIK: 0001533040 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36304 | Film No.: 22710266
SIC: 2834 Pharmaceutical Preparations